Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Prevalence and Pathogenesis

Expert recap of highlights from the NASH Core Curriculum, including pathogenesis, risk factors, and current and emerging therapies for patients with NAFLD/NASH.
Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC
Released: September 9, 2021 Expiration: No longer available for credit

This program is divided into several short segments that you can access using the Video Chapters menu.
PreviousNext

Related Content

Expert commentary on disease nomenclature based on underlying genetic factors, NASH heterogeneity, from Clinical Care Options (CCO)

Brent A. Neuschwander-Tetri, MD Released: September 29, 2022

Expert insight on the burden and impact of HBV infection, as well as strategies to overcome barriers to vaccination, from Clinical Care Options (CCO)

Robert G. Gish, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 22, 2022 Expired: March 21, 2023

Free slides from CCO featuring data on the prevalence, assessment, and treatment landscape for NASH in people living with HIV.

Jürgen K. Rockstroh, MD Giada Sebastiani, MD Released: February 9, 2022

Expert commentary by Dr Mark S. Sulkowski on the importance of investigating elevated liver enzymes in patients with HIV, from Clinical Care Options (CCO)

Mark S. Sulkowski, MD Released: January 10, 2022

Video Chapters


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences
Novo Nordisk Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings